GPHL has been developing rapidly yet sustainably, and has become Guangzhou’s second SOE to achieve in excess of 100-billion-yuan revenue. It has also claimed the top spot among Chinese pharmaceutical manufactures for seven consecutive years now.

In addition, GPHL is currently expanding its business, developing the four main business arms---pharmaceuticals, healthcare, marketing, and medical treatment and boosting three new business models, that is, e-commerce, capital finance and medical equipment.

It places great importance on innovation. Last year, GPHL received permission to conduct clinical trials with Ceftriamidine Sodium and Ceftriamidine Sodium for Injection, a new drug to treat pneumonia. The drug is the only new class 1.1 cephalosporin drug to have gained this permit over the past two decades. In addition, GPHL has been granted one American and two Chinese patents on inventions.

Benefiting from Guangzhou’s efforts to develop IAB industries (information technology, artificial intelligence and bio-technology), GPHL has taken this opportunity to focus on the R&D of antineoplastic drugs and vaccines. According to the company, 13 new types of these drugs are under research.

Furthermore, GPHL has developed the strategies to popularize Chinese traditional medicine and to focus on building big brands.

As both the biggest pharmaceutical company and Chinese traditional medicine manufacturer nationwide, GPHL will continue to take its social responsibilities seriously and improve its capacity to innovate, aiming to offer better products and services to consumers and to promote the pharmaceutical industry’s overall development.

GPHL’s next goal is to make the Fortune Global 500 List by 2020.